Combined High Dose Radiotherapy with Sequential Gemcitabine-Cisplatin Based Chemotherapy Increase the Resectability and Survival in Locally Advanced Unresectable Intrahepatic Cholangiocarcinoma: A Multi-Institutional Cohort Study
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose The locally advanced unresectable intrahepatic cholangiocarcinoma (ICC) has detrimental oncological outcomes. In this study, we aimed to investigate the efficacy of radiotherapy in patients with locally advanced unresectable ICC. Materials and Methods Between 2001 and 2021, 116 patients were identified through medical record who underwent radiotherapy for locally advanced unresectable ICC. The resectability of ICC is determined by the multidisciplinary team at each institution. Overall survival (OS) were analyzed using the Kaplan-Meier method, and prognostic factors were analyzed using the Cox proportional hazards model. Results The median equivalent radiotherapy dose in 2 Gy fractions (EQD2) was 52 Gy (range, 30 to 110 Gy). Forty-seven patients (40.5%) received sequential gemcitabine-cisplatin based chemotherapy (GEM-CIS CTx). Multivariate analysis identified two risk factors, EQD2 of ≥ 60 Gy and application of sequential GEM-CIS CTx for OS. Patients were grouped by these two risk factors: group 1, EQD2 ≥ 60 Gy with sequential GEM-CIS CTx (n=25); group 2, EQD2 < 60 Gy with sequential GEM-CIS CTx or fluoropyrimidine-based concurrent chemoradiotherapy (n=70); and group 3, radiotherapy alone (n=21). Curative resection was more frequently undergone in group 1 than in groups 2 or 3 (28% vs. 8.6% vs. 0%, respectively). Consequently, OS was significantly better in group 1 than in groups 2 and 3 (p < 0.05). Conclusion Combined high-dose radiotherapy with sequential GEM-CIS CTx improved oncologic outcomes in patients with locally advanced unresectable ICC. Further prospective studies are required to validate these findings.
Abstract
Purpose The locally advanced unresectable intrahepatic cholangiocarcinoma (ICC) has detrimental oncological outcomes. In this study, we aimed to investigate the efficacy of radiotherapy in patients with locally advanced unresectable ICC. Materials and Methods Between 2001 and 2021, 116 patients were identified through medical record who underwent radiotherapy for locally advanced unresectable ICC. The resectability of ICC is determined by the multidisciplinary team at each institution. Overall survival (OS) were analyzed using the Kaplan-Meier method, and prognostic factors were analyzed using the Cox proportional hazards model. Results The median equivalent radiotherapy dose in 2 Gy fractions (EQD2) was 52 Gy (range, 30 to 110 Gy). Forty-seven patients (40.5%) received sequential gemcitabine-cisplatin based chemotherapy (GEM-CIS CTx). Multivariate analysis identified two risk factors, EQD2 of ≥ 60 Gy and application of sequential GEM-CIS CTx for OS. Patients were grouped by these two risk factors: group 1, EQD2 ≥ 60 Gy with sequential GEM-CIS CTx (n=25); group 2, EQD2 < 60 Gy with sequential GEM-CIS CTx or fluoropyrimidine-based concurrent chemoradiotherapy (n=70); and group 3, radiotherapy alone (n=21). Curative resection was more frequently undergone in group 1 than in groups 2 or 3 (28% vs. 8.6% vs. 0%, respectively). Consequently, OS was significantly better in group 1 than in groups 2 and 3 (p < 0.05). Conclusion Combined high-dose radiotherapy with sequential GEM-CIS CTx improved oncologic outcomes in patients with locally advanced unresectable ICC. Further prospective studies are required to validate these findings.
참고문헌 (26)
- Glimelius B, "Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer", Ann Oncol, 7, pp.593~600 (1996)
- Valle J, "Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer", N Engl J Med, 362, pp.1273~1281 (2010)
- Okusaka T, "Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer : a comparative multicentre study in Japan", Br J Cancer, 103, pp.469~474 (2010)
- Valle JW, "Cisplatin and gemcitabine for advanced biliary tract cancer : a meta-analysis of two randomised trials", Ann Oncol, 25, pp.391~398 (2014)
- Oh DY, "A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin(GemCis)in patients(pts)with advanced biliary tract cancer(BTC) : TOPAZ-1", J Clin Oncol, 40(4 Suppl), pp.378~ (2022)
- Kelley RK, "Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer(KEYNOTE-966) : a randomised, double-blind, placebo-controlled, phase 3 trial", Lancet, 401, pp.1853~1865 (2023)
- Lamarca A, "Advanced intrahepatic cholangiocarcinoma : post hoc analysis of the ABC-01, -02, and-03 clinical trials", J Natl Cancer Inst, 112, pp.200~210 (2020)
- Yamashita S, "Local therapy reduces the risk of liver failure and improves survival in patients with intrahepatic cholangio-carcinoma : a comprehensive analysis of 362 consecutive pati-ents", Cancer, 123, pp.1354~1362 (2017)
- Tao R, "Ablative radiotherapy doses lead to a substantial prolongation of survival in patients with inoperable intrahepatic cholangiocarcinoma : a retrospective dose response analysis", J Clin Oncol, 34, pp.219~226 (2016)
- Hong TS, "Multi-institutional phase II study of high-dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma", J Clin Oncol, 34, pp.460~468 (2016)
- De B, "Ablative liver radiotherapy for unresected intrahepatic cholangiocarcinoma : patterns of care and survival in the United States", Cancer, 128, pp.2529~2539 (2022)
- Smart AC, "Hypofractionated radiation therapy for unresectable", locally recurrent intrahepatic cholangiocarcinoma, 2020, pp.27, 1122~1129
- Apisarnthanarax S, "External beam radiation therapy for primary liver cancers : an ASTRO clinical practice guideline", Pract Radiat Oncol, 12, pp.28~51 (2022)
- Chang WW, "Treatment outcomes for unresectable intrahepatic cholangiocarcinoma : nationwide, population-based, cohort study based on propensity score matching with the Mahalanobis metric", Radiother Oncol, 129, pp.284~292 (2018)
- Jackson MW, "Treatment selection and survival outcomes with and without radiation for unresectable, localized intrahepatic cholangiocarcinoma", Cancer J, 22, pp.237~242 (2016)
- Kim YI, "Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for advanced-stage unresectable intrahepatic cholangiocarcinoma", Radiat Oncol, 8, pp.292~ (2013)
- Verma V, "Chemoradiotherapy versus chemotherapy alone for unresected intrahepatic cholangiocarcinoma : practice patterns and outcomes from the national cancer data base", J Gastrointest Oncol, 9, pp.527~535 (2018)
- Bridgewater J, "Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma", J Hepatol, 60, pp.1268~1289 (2014)
- Guro H, "Multidisciplinary management of intrahepatic cholangiocarcinoma : Current approaches", Surg Oncol, 26, pp.146~152 (2017)
- Joiner MC, "A simple alpha", beta-independent method to derive fully isoeffective schedules following changes in dose per fraction, 2004, pp.58, 871~875
- Lencioni R, "Modified RECIST(mRECIST)assessment for hepatocellular carcinoma", Semin Liver Dis, 30, pp.52~60 (2010)
- Sebastian NT, "Association of liver-directed local therapy with overall survival in adults with metastatic intrahepatic cholangiocarcinoma", JAMA Netw Open, 2, pp.e1911154~ (2019)
- Brunner TB, "Stereotactic body radiotherapy dose and its impact on local control and overall survival of patients for locally advanced intrahepatic and extrahepatic cholangiocarcinoma", Radiother Oncol, 132, pp.42~47 (2019)
- Kozak MM, "Stereotactic body radiation therapy for cholangiocarcinoma : optimizing locoregional control with elective nodal irradiation", Adv Radiat Oncol, 5, pp.77~84 (2020)
- Ohkawa A, "Proton beam therapy for unresectable intrahepatic cholangiocarcinoma", J Gastroenterol Hepatol, 30, pp.957~963 (2015)
- Shroff RT, "SWOG 1815: a phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers", J Clin Oncol, 41(4 Suppl), pp.LBA490~ (2023)